SEC Probing King Pricing and Rebates
From Reuters
King Pharmaceuticals Inc. said securities regulators are investigating its pricing and rebate practices and have subpoenaed various documents.
The drug maker said it received a letter and a subpoena from the Securities and Exchange Commission. King’s auditors, PricewaterhouseCoopers, also received a subpoena about the company.
Shares of Bristol, Tenn.-based King fell $3.73 to close at $12.17 on the New York Stock Exchange.
